use of topotecan in the manufacture of a medicinal product for use in the treatment of ovarian cancer

摘要

The invention relates to a pharmaceutical composition comprising topotecan, for use in the treatment of ovarian cancer in a human afflicted therewith, wherein the composition is for parenteral administration to such human employing a course of therapy of from 1.0 to 2.5 mg (e.g. about 1.5 to about 2 mg) of topotecan/m 2 of body surface area per day for about five consecutive days. The invention also relates to a pharmaceutical composition comprising topotecan, for use in the treatment of ovarian cancer in a human afflicted therewith, wherein the composition is for oral administration to such human employing a course of therapy of from 1.5 to 5.0 mg of topotecan/m 2 of body surface area per day for about five consecutive days. The pharmaceutical composition can be an oral or parenteral pharmaceutical composition comprising topotecan and an inert, pharmaceutically acceptable carrier or diluent.